Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

TriSalus Life Sciences, Inc. - Common Stock (NQ:TLSI)

3.960 -0.060 (-1.49%)
Streaming Delayed Price Updated: 10:13 AM EDT, Mar 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about TriSalus Life Sciences, Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
TriSalus Life Sciences Announces Publication Demonstrating Enhanced Delivery and Immune Activation with Nelitolimod Delivered with Pressure-Enabled Drug Delivery in Liver Tumor Models
From TriSalus Life Sciences
Via Business Wire
TriSalus Life Sciences Inc (NASDAQ:TLSI) Reports Q4 Revenue Beat and Narrowed Losses ↗
Via Chartmill
News headline image
TriSalus (TLSI) Q4 2025 Earnings Call Transcript ↗
TriSalus (TLSI) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
TriSalus Life Sciences Reports Fourth Quarter and Year-End 2025 Results and Reaffirms 2026 Revenue Guidance
From TriSalus Life Sciences
Via Business Wire
News headline image
Earnings Scheduled For November 13, 2025 ↗
 
Via Benzinga
News headline image
TriSalus Life Sciences to Host Fourth Quarter 2025 Financial Results Conference Call
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences Announces Pricing of $40.0 Million Public Offering
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences Proposes Public Offering
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences Appoints Veteran Healthcare Investor Michael Stansky to its Board of Directors
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences Announces Preliminary Fourth Quarter and Full-Year 2025 Results and 2026 Revenue Guidance
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences to Host Virtual KOL Event to Discuss the TriNav Infusion System for the Treatment of Symptomatic Thyroid Disease on December 15, 2025
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences Launches TriNav® XP Infusion System to Expand Options for Pressure-Enabled Drug Delivery™
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences Inc (NASDAQ:TLSI) Reports Q3 2025 Results with Strong Revenue Growth but Significant EPS Miss ↗
TriSalus Q3 2025 results show strong 57% revenue growth but a wider-than-expected EPS loss. The company reaffirmed its 50% full-year growth outlook. 
Via Chartmill
News headline image
TriSalus (TLSI) Q3 2025 Earnings Call Transcript ↗
TriSalus (TLSI) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
TriSalus Life Sciences Reports Third Quarter 2025 Results and Reaffirms 2025 Revenue Guidance
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences to Participate in Upcoming Investor Conferences
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences to Host Virtual KOL Event to Discuss the TriNav Infusion System for the Treatment of Uterine Fibroids on November 12, 2025
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences to Host Third Quarter 2025 Financial Results Conference Call
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences to Participate in Upcoming September Investor Conferences
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences Inc (NASDAQ:TLSI) Reports Strong Q2 2025 Revenue Growth and Narrowed Losses ↗
TriSalus Life Sciences reports strong Q2 2025 revenue growth of 52% YoY to $11.2M, beating estimates. Losses narrow as commercialization of TriNav and PEDD platform gains momentum. 
Via Chartmill
News headline image
TriSalus Life Sciences Reports Second Quarter 2025 Results and Reiterates 2025 Guidance
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences Announces Publication of Safety and Efficacy Results for a Novel Pressure-Enabled Thyroid Embolization Technique
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences to Participate in the Canaccord Genuity 45th Annual Growth Conference
From TriSalus Life Sciences
Via Business Wire
News headline image
Earnings Scheduled For August 12, 2025 ↗
 
Via Benzinga
News headline image
TriSalus Life Sciences to Host Second Quarter 2025 Financial Results Conference Call
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock to Streamline Capital Structure
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences Announces the Launch of the TriNav FLX Infusion System
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences Announces Chief Financial Officer Transition With Appointment of David B. Patience
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences Reports First Quarter 2025 Results and Provides Updated 2025 Guidance
From TriSalus Life Sciences
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.